{"id":"W4405038833","doi":"10.1182/blood-2024-199281","title":"Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"MorphoSys; Swedish Orphan Biovitrum; Incyte; BeiGene; Gilead Sciences; Merck KGaA; Genentech; MEI Pharma; NYU Grossman School of Medicine; Regeneron Pharmaceuticals; Seagen; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Refractory (planetary science); Medicine; Salvage therapy; Ibrutinib; Internal medicine; Maximum tolerated dose; Oncology; Adverse effect; Chemotherapy; Leukemia; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001358023,0.001378283,0.001153283,0.0003865667,0.0004033706,0.0008332894,0.0006980893,0.0008513879,0.003187696],"category_scores_gemma":[0.000709802,0.0004571647,0.001284748,0.0003383749,0.000615767,0.0006239652,0.0002418345,0.002987789,0.0009330746],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009124267,"about_ca_system_score_gemma":0.001203812,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00110525,"about_ca_topic_score_gemma":0.004460244,"domain_scores_codex":[0.9996432,0.0001268838,0.00002274671,0.00008044731,0.00004744947,0.00007923559],"domain_scores_gemma":[0.9995047,0.00007867401,0.00008209344,0.00005384682,0.0000432064,0.0002374574],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2829752,0.1398803,0.01441142,0.001709325,0.003939429,0.00124387,0.001013782,0.01025481,0.2584047,0.0007330035,0.0188434,0.2665906],"study_design_scores_gemma":[0.2239088,0.6876767,0.04344178,0.00007317089,0.001662448,0.001628437,0.0001611501,0.002534761,0.02416322,0.0005872747,0.01408862,0.0000738145],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985008,0.002926532,0.001408378,0.0007896918,0.00009828252,0.002577309,0.003152673,0.0001795514,0.003859581],"genre_scores_gemma":[0.9860144,0.001685877,0.002367115,0.0009696092,0.00007613734,0.001204576,0.004021812,0.00004596416,0.003614539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003187696,"threshold_uncertainty_score":0.01066387,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00930047824764595,"score_gpt":0.2679317796691109,"score_spread":0.258631301421465,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}